Sana Biotechnology (NASDAQ:SANA) Given New $7.00 Price Target at HC Wainwright

Sana Biotechnology (NASDAQ:SANA) had its price objective lowered by HC Wainwright from $9.00 to $7.00 in a report published on Wednesday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Monday, December 29th. Wedbush increased their price target on shares of Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Bank of America lifted their price objective on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Zacks Research upgraded Sana Biotechnology from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. Finally, Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.83.

Sana Biotechnology Price Performance

Shares of NASDAQ SANA opened at $3.82 on Wednesday. The business has a fifty day moving average price of $4.30 and a two-hundred day moving average price of $4.14. The stock has a market capitalization of $1.02 billion, a PE ratio of -3.94 and a beta of 1.96. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03). On average, equities analysts expect that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Nisa Investment Advisors LLC grew its position in Sana Biotechnology by 673.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock worth $30,000 after acquiring an additional 9,501 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Sana Biotechnology in the 3rd quarter valued at approximately $36,000. TD Waterhouse Canada Inc. acquired a new stake in Sana Biotechnology during the 3rd quarter worth approximately $37,000. Lyell Wealth Management LP bought a new stake in Sana Biotechnology during the 3rd quarter worth approximately $37,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in Sana Biotechnology in the 3rd quarter valued at approximately $39,000. 88.23% of the stock is currently owned by institutional investors.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.